ALMS Alumis Inc.

Alumis Inc. (NASDAQ:ALMS) reported that the 408-patient Phase 2b LUMUS trial of envudeucitinib in moderate-to-severe systemic lupus erythematosus did not meet its primary or secondary endpoints in the overall population. Envudeucitinib is an investigational oral inhibitor of tyrosine kinase 2, or TYK2. The primary endpoint was the British Isles Lupus Assessment Group-based Composite Lupus Assessment, […]

Alumis stock presents a sharp disconnect between recent share price swings and what broad valuation checks suggest. After a very strong 1 year return, the company now screens as expensive on the wider metrics, even after a steep pullback following mixed trial news. Alumis has delivered a 121.2% return over the past year, which puts extra focus on whether the current price already reflects much of the good news investors expect. The recent Phase 2b LUMUS trial setback in lupus, together with...

In early September 2026, Alumis reported that its Phase 2b LUMUS trial of envudeucitinib in moderate-to-severe systemic lupus erythematosus failed to meet primary and secondary endpoints in the overall patient population, despite a favorable safety profile over 48 weeks. An important finding was that a prespecified subgroup of patients with a high interferon gene signature showed robust clinical responses, supporting Alumis’ plan to pursue biomarker-driven Phase 3 development and an NDA in...

Alumis (ALMS) is back in focus after reporting that envudeucitinib missed primary and secondary endpoints in the Phase 2b LUMUS lupus trial, while a predefined interferon gene signature high subgroup showed stronger clinical responses. That mixed trial readout has gone hand in hand with sharp share price volatility, with a 7 day share price return of down 56.18% and a 30 day share price return of down 60.38%. Alumis still shows a year to date share price return of 15.58% and a 1 year total...

Alumis (NasdaqGS: ALMS) reported that its lead drug envudeucitinib did not meet primary or secondary endpoints in a Phase 2b lupus trial. The company highlighted strong efficacy and safety signals in a genetically defined IFNGS high subgroup of lupus patients within the study. Alumis plans to continue developing envudeucitinib and discuss potential regulatory paths for broader immune mediated indications based on the subgroup data. This update on Alumis shows how targeted drug development...

Healthcare stocks were higher late Wednesday afternoon, with the NYSE Healthcare Index and the State

Purple Biotech (PPBT) said Wednesday that the US Patent and Trademark Office has issued a "Notice of

Healthcare stocks were higher Wednesday afternoon, with the NYSE Healthcare Index adding 0.7% and th

Alumis' (ALMS) share price drop after the disappointing results of a phase 2b trial of envudeucitini

The selloff followed topline results from the Phase 2b LUMUS trial of envudeucitinib in moderate-to-severe systemic lupus erythematosus, or SLE, a chronic autoimmune disease in which the body's immune system mistakenly attacks healthy tissues.

Tesla trades lower even as investors anticipate the potential entry of Cybercab into the company’s fleet of self-driving cabs.

Healthcare stocks were higher late Tuesday afternoon, with the NYSE Healthcare Index adding 0.6% and

Alumis shares sink after the California-based biotech says envudeucitinib failed to meet the primary endpoint of a mid-stage trial.

Alumis (NASDAQ:ALMS) said its Phase II LUMUS trial of envudeucitinib in systemic lupus erythematosus, or SLE, did not meet its primary or key secondary endpoints in the overall study population. However, the company said pre-specified analyses showed clinically meaningful responses among patients wi

Alumis Inc. (Nasdaq: ALMS) said its Phase 2b LUMUS trial evaluating envudeucitinib in patients with moderate-to-severe systemic lupus erythematosus (SLE) did not meet its primary or secondary endpoints in the overall study population.

Though Alumis still sees a path forward in lupus, the result made its drug the latest TYK2 blocker to struggle in conditions beyond psoriasis and psoriatic arthritis.

PTGX, ALMS, ORKA and VNDA offer diverse psoriasis opportunities, spanning approved therapies, late-stage candidates and earlier-stage programs.

Prothena (PRTA) delivered earnings and revenue surprises of +17.95% and -1.94%, respectively, for the quarter ended June 2026. Do the numbers hold clues to what lies ahead for the stock?